The National MPS Society’s research program has awarded Crosswalk Therapeutics a grant to advance a new therapeutic approach for MPS IVA (Morquio A syndrome). The funded research will support preclinical proof-of-concept studies for a fusion protein designed to improve both enzyme performance and delivery to disease-relevant tissues. The program is specifically focused on addressing limitations of existing enzyme therapies in skeletal tissues.
“The National MPS Society has a mandate to find and fund promising research, and we are pleased to provide support for Crosswalk’s early development of a next–generation enzyme replacement for MPS IVA,” said Scott Loiler, PhD, Chief Scientific Officer at the Society.
“We are honored to partner with the National MPS Society and motivated by their commitment to funding science that directly addresses the realities faced by individuals and families living with Morquio A,” said Madhu Natarajan, PhD, Chief Executive Officer of Crosswalk.
For all questions or comments, please get in touch with Dr. Loiler at scott@mpssociety.org.
